Looking for space?
Login

Research Associate Bioconjugation

Synaffix B.V. is a Dutch biotechnology company focused on the advancement of our technology platform for best-in-class antibody-drug conjugates (ADCs) (see: www.synaffix.com). As a leading innovator in the field, there are now three ADCs in the clinic and >20 in preclinical development through our partnered programs. Our vision is to become world-wide the most prevalent ADC technology for pharma and biotech companies and to realize our ambition – Connect to Cure.

As a result of the increasing number of external ADC collaborations, we are currently looking for a skilled and enthusiastic

Research Associate Bioconjugation
(0.8–1 fte)

Requirements:

  • B.Sc. or M.Sc. degree in chemical biology, biochemistry, biomedical engineering or related fields
  • Experience with various protein purification and analysis techniques including SEC, IEX, affinity
    chromatography (protein A/L, Ni-NTA), SDS-PAGE, RP-HPLC and MS.
  • Experience with handling antibodies, including modification, purification and analysis.
  • Familiarity with various bioconjugation chemistry technics and preferably hands-on experience
  • Enthusiastic, dedicated, responsible, accurate and conscientious character
  • Ability to operate in a team with joint project responsibilities
  • Proper English communication skills, both verbal and in writing

 

Job description:
You will operate in a team that supports the preparation of ADCs for external collaborations with biotech/pharma companies. Key tasks include setting up experiments, running reactions and purifying intermediates and final products. You will interpretate your results and perform process adjustments if required. In addition you will characterize the produced ADCs with various analytical tools and where
applicable perform activity determination in cellular assays. Furthermore, general support to lab operations will also be part of your day-to-day activities.

What is offered:
A position as Research Associate Bioconjugation Chemistry in a vibrant growing organization with opportunities for further learning and personal development. Synaffix offers a competitive renumeration package including secundary benefits such as 8% holiday allowance, 25 days annual leave on a full-time basis as well as a collective pension with a fixed percentage personal contribution.

How to contact us:
For further information or to apply for this position please contact Dr. Sander van Berkel via
careers@synaffix.com. Deadline for application submission (CV and motivation letter) is Feb 17
th 2023. More information about Synaffix’ company profile can be found on our Linkedin page: https://www.linkedin.com/company/synaffix-bv/

< Back to careers

Company:

Other vacancies

Looking for
space to grow?

More information
Join us at Pivot Park

Learn about
our companies?

Send us a message
Contact us at Pivot Park

or call

+31 (0)412 84 60 10

Disclaimer | Privacy Policy | Purchase conditions
Address

Pivot Park –
Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com

Linkedin-in Youtube
Post address

Pivot Park  Exploitatie B.V. 
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?
Read more (NL)

#100YEARSPHARMAFUTURE

The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.